Get the Stockscreener App
6.845
3.05%
-0.185
Valneva Se Adr stock is traded at $6.845, with a volume of 5,962.
It is down -3.05% in the last 24 hours and down -12.51% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
See More
Previous Close:
$7.03
Open:
$6.91
24h Volume:
5,962
Relative Volume:
0.10
Market Cap:
$561.08M
Revenue:
$163.13M
Net Income/Loss:
$-34.75M
P/E Ratio:
-13.29
EPS:
-0.5152
Net Cash Flow:
$-231.66M
1W Performance:
-0.65%
1M Performance:
-12.51%
6M Performance:
+6.74%
1Y Performance:
-8.76%
1-Day Range:
$6.8009
$6.91
1-Week Range:
$6.71
$7.29
52-Week Range:
$3.62
$9.50
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.845 | 561.08M | 163.13M | -34.75M | -231.66M | -0.5152 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.17 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.01 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.05 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.79 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.13 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Stockholders to Connect - Markets Insider
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Stockholders to Learn More About the Investigation. - Markets Insider
ATTENTION VALN SHAREHOLDERS: Investors who lost money on Valneva SE are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Investors to Inquire about Securities Investigation - Markets Insider
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Investors to Reach Out - Markets Insider
H.C. Wainwright cuts Valneva stock target to $17, maintains Buy By Investing.com - Investing.com South Africa
Déclaration d'actions et de droits de vote de la société Valneva SE - GlobeNewswire Inc.
Valneva stock holds $18 target on UK vaccine nod - Investing.com India
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock - Yahoo Finance
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine - GlobeNewswire Inc.
VALNEVA - GlobeNewswire Inc.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock - Yahoo Finance
Valneva SE earnings missed by $0.02, revenue fell short of estimates - Investing.com
Valneva SE (VALN) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Valneva SE stock, lowers price target - Investing.com
Valneva SE Declaration of shares and voting rights - GlobeNewswire Inc.
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy - Investing.com
H.C. Wainwright updates Valneva SE outlook following capital raise, reiterates Buy By Investing.com - Investing.com South Africa
In-Depth Examination Of 6 Analyst Recommendations For Valneva - Benzinga
Valneva shares hold strong with buy rating on Lyme vaccine data - Investing.com
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock - Yahoo Finance
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know - Yahoo Finance
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3% - Yahoo Finance
Valneva (VALN) Stock Down 53% in the Past Year: Here's Why - Nasdaq
Valneva (VALN) Down as EU Considers Ending COVID-Vaccine Deal - Yahoo Finance
Valneva Stock Is Jumping on European Vaccine Supply Deal - Barron's
Valneva Stock Surges After EU Vaccine Deal - Investing.com
Valneva (VALN) Reports Positive Data From COVID Vaccine Study - Nasdaq
Valneva Stock Plunges as U.K. Drops Covid-19 Vaccine Deal - Barron's
EU set to sign off new Pfizer vaccine contract as soon as Friday - Luxembourg Times
Shareholder Structure - Valneva
Stock Price - Valneva
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):